{"id":"https://openalex.org/W7148962025","doi":"https://doi.org/10.1158/1538-7445.am2026-4536","title":"Abstract 4536: GFS784, a next-generation ADC with a novel panRAS(ON) inhibitor payload","display_name":"Abstract 4536: GFS784, a next-generation ADC with a novel panRAS(ON) inhibitor payload","publication_year":2026,"publication_date":"2026-04-03","ids":{"openalex":"https://openalex.org/W7148962025","doi":"https://doi.org/10.1158/1538-7445.am2026-4536"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2026-4536","doi":"https://doi.org/10.1158/1538-7445.am2026-4536","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2026-4536","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5132899719","display_name":"Feng Yan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267115","display_name":"Genfleet Therapeutics (Shanghai) Inc. (China)","ror":"https://ror.org/01950kj80","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267115"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Feng Yan","raw_affiliation_strings":["Genfleet Therapeutics, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genfleet Therapeutics, Shanghai, China","institution_ids":["https://openalex.org/I4405267115"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5132839338","display_name":"Jichen Zhao","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267115","display_name":"Genfleet Therapeutics (Shanghai) Inc. (China)","ror":"https://ror.org/01950kj80","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267115"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Jichen Zhao","raw_affiliation_strings":["Genfleet Therapeutics, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genfleet Therapeutics, Shanghai, China","institution_ids":["https://openalex.org/I4405267115"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5132852427","display_name":"Jingyang Zhang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267115","display_name":"Genfleet Therapeutics (Shanghai) Inc. (China)","ror":"https://ror.org/01950kj80","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267115"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Jingyang Zhang","raw_affiliation_strings":["Genfleet Therapeutics, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genfleet Therapeutics, Shanghai, China","institution_ids":["https://openalex.org/I4405267115"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5132877420","display_name":"Li Wang","orcid":"https://orcid.org/0000-0002-1459-3412","observed_orcids":["https://orcid.org/0000-0002-1459-3412"]},"institutions":[{"id":"https://openalex.org/I4405267115","display_name":"Genfleet Therapeutics (Shanghai) Inc. (China)","ror":"https://ror.org/01950kj80","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267115"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Li Wang","raw_affiliation_strings":["Genfleet Therapeutics, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genfleet Therapeutics, Shanghai, China","institution_ids":["https://openalex.org/I4405267115"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101903762","display_name":"Yumei Li","orcid":"https://orcid.org/0000-0001-9618-3865","observed_orcids":["https://orcid.org/0000-0001-9618-3865"]},"institutions":[{"id":"https://openalex.org/I4405267115","display_name":"Genfleet Therapeutics (Shanghai) Inc. (China)","ror":"https://ror.org/01950kj80","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267115"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yumei Li","raw_affiliation_strings":["Genfleet Therapeutics, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genfleet Therapeutics, Shanghai, China","institution_ids":["https://openalex.org/I4405267115"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002088038","display_name":"Siyuan Le","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267115","display_name":"Genfleet Therapeutics (Shanghai) Inc. (China)","ror":"https://ror.org/01950kj80","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267115"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Siyuan Le","raw_affiliation_strings":["Genfleet Therapeutics, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genfleet Therapeutics, Shanghai, China","institution_ids":["https://openalex.org/I4405267115"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102889826","display_name":"Fusheng Zhou","orcid":"https://orcid.org/0000-0002-6277-906X","observed_orcids":["https://orcid.org/0000-0002-6277-906X"]},"institutions":[{"id":"https://openalex.org/I4405267115","display_name":"Genfleet Therapeutics (Shanghai) Inc. (China)","ror":"https://ror.org/01950kj80","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267115"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Fusheng Zhou","raw_affiliation_strings":["Genfleet Therapeutics, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genfleet Therapeutics, Shanghai, China","institution_ids":["https://openalex.org/I4405267115"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102786156","display_name":"Jiong Lan","orcid":"https://orcid.org/0000-0002-8114-2427","observed_orcids":["https://orcid.org/0000-0002-8114-2427"]},"institutions":[{"id":"https://openalex.org/I4405267115","display_name":"Genfleet Therapeutics (Shanghai) Inc. (China)","ror":"https://ror.org/01950kj80","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267115"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Jiong Lan","raw_affiliation_strings":["Genfleet Therapeutics, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genfleet Therapeutics, Shanghai, China","institution_ids":["https://openalex.org/I4405267115"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5132905091","display_name":"Qiang Lu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267115","display_name":"Genfleet Therapeutics (Shanghai) Inc. (China)","ror":"https://ror.org/01950kj80","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267115"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Qiang Lu","raw_affiliation_strings":["Genfleet Therapeutics, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genfleet Therapeutics, Shanghai, China","institution_ids":["https://openalex.org/I4405267115"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4405267115"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"86","issue":"7_Supplement","first_page":"4536","last_page":"4536"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.6929000020027161,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.6929000020027161,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12477","display_name":"Toxin Mechanisms and Immunotoxins","score":0.07320000231266022,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10169","display_name":"Protein Kinase Regulation and GTPase Signaling","score":0.06750000268220901,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.902999997138977},{"id":"https://openalex.org/keywords/pan-ras-inhibitors","display_name":"pan-RAS inhibitors","score":0.6830000281333923},{"id":"https://openalex.org/keywords/cyclophilin-a","display_name":"cyclophilin A","score":0.7979999780654907},{"id":"https://openalex.org/keywords/egfr","display_name":"EGFR","score":0.7400000095367432},{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":0.9829999804496765},{"id":"https://openalex.org/keywords/bystander-effect","display_name":"bystander effect","score":0.7609999775886536},{"id":"https://openalex.org/keywords/plasma-stability","display_name":"plasma stability","score":0.5960000157356262},{"id":"https://openalex.org/keywords/rmc-6236","display_name":"RMC-6236","score":0.8180000185966492},{"id":"https://openalex.org/keywords/ras-wild-type","display_name":"RAS wild-type","score":0.3330000042915344}],"concepts":[{"id":"https://openalex.org/C134066672","wikidata":"https://www.wikidata.org/wiki/Q1424639","display_name":"Payload (computing)","level":3,"score":0.7049999833106995},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.595300018787384},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5598000288009644},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5450999736785889},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.5228999853134155},{"id":"https://openalex.org/C143065580","wikidata":"https://www.wikidata.org/wiki/Q3285695","display_name":"Mutant","level":3,"score":0.5105000138282776},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.4569000005722046},{"id":"https://openalex.org/C2780557392","wikidata":"https://www.wikidata.org/wiki/Q523796","display_name":"Linker","level":2,"score":0.45649999380111694},{"id":"https://openalex.org/C2777325958","wikidata":"https://www.wikidata.org/wiki/Q1069596","display_name":"Antibody-drug conjugate","level":4,"score":0.4383000135421753},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.42899999022483826},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.3774000108242035},{"id":"https://openalex.org/C207583985","wikidata":"https://www.wikidata.org/wiki/Q128723","display_name":"Wild type","level":4,"score":0.375900000333786},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.3727000057697296},{"id":"https://openalex.org/C19106626","wikidata":"https://www.wikidata.org/wiki/Q230749","display_name":"Bystander effect","level":2,"score":0.35850000381469727},{"id":"https://openalex.org/C54009773","wikidata":"https://www.wikidata.org/wiki/Q1429031","display_name":"Transfection","level":3,"score":0.3580000102519989},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.3192000091075897},{"id":"https://openalex.org/C197336794","wikidata":"https://www.wikidata.org/wiki/Q5161150","display_name":"Conjugate","level":2,"score":0.3188999891281128},{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.3093000054359436},{"id":"https://openalex.org/C501734568","wikidata":"https://www.wikidata.org/wiki/Q42918","display_name":"Mutation","level":3,"score":0.28060001134872437},{"id":"https://openalex.org/C2776217527","wikidata":"https://www.wikidata.org/wiki/Q944828","display_name":"Sensitization","level":2,"score":0.27639999985694885},{"id":"https://openalex.org/C64903051","wikidata":"https://www.wikidata.org/wiki/Q2198549","display_name":"Drug development","level":3,"score":0.27239999175071716},{"id":"https://openalex.org/C127561419","wikidata":"https://www.wikidata.org/wiki/Q224527","display_name":"Downregulation and upregulation","level":3,"score":0.265500009059906},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.26440000534057617},{"id":"https://openalex.org/C174510640","wikidata":"https://www.wikidata.org/wiki/Q489618","display_name":"HEK 293 cells","level":3,"score":0.25940001010894775},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2581000030040741},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.2574999928474426},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.2529999911785126}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2026-4536","doi":"https://doi.org/10.1158/1538-7445.am2026-4536","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2026-4536","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9391000270843506,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7148892771","https://openalex.org/W4409631958","https://openalex.org/W7148981926","https://openalex.org/W2909634290","https://openalex.org/W7148745983","https://openalex.org/W7214346377","https://openalex.org/W1651223554","https://openalex.org/W4412538326","https://openalex.org/W2886389123","https://openalex.org/W7149018468"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Antibody":[2,57],"drug":[3,10],"conjugate":[4],"(ADC)":[5],"has":[6,351],"proven":[7],"an":[8,34,77,86,90,148,158,227,262,357,380],"effective":[9,362],"modality":[11],"and":[12,30,52,58,208,220,233,281,318,343,379,399],"keeps":[13],"evolving":[14],"with":[15,105,129,157,250,313,430],"innovations":[16],"explored":[17],"on":[18,144],"each":[19],"of":[20,33,45,76,85,117,122,136,147,165,189,261,288,439],"its":[21,142],"components.":[22],"However,":[23],"the":[24,28,31,43,55,67,73,145,185,309,373,440],"potential":[25,374],"coordination":[26],"between":[27],"antibody":[29],"payload":[32,51,195,435],"ADC":[35,63,78,92,358,369,378,429],"is":[36,93,256,361,404],"usually":[37],"overlooked":[38],"efficacy-wise.":[39],"Here":[40],"we":[41],"introduce":[42],"development":[44],"a":[46,61,106,111,251,352,376,389,400,427,431],"novel":[47,62,432],"panRAS":[48],"(ON)":[49],"inhibitor":[50,108,194,434],"more":[53],"importantly,":[54],"Functional":[56],"Synergistic":[59],"conjugate(FASconTM),":[60],"design":[64],"which":[65,255,302],"employes":[66,197],"antibody-payload":[68],"synergy":[69],"to":[70,183,200,219,243,308,367],"further":[71,401],"enhance":[72],"therapeutic":[74,296],"activity":[75,121,212,236],"beyond":[79],"precision":[80],"delivery.":[81],"The":[82,119,133,162,192],"preclinical":[83,354],"profile":[84,355],"exemplified":[87],"FAScon":[88],"GFS784,":[89,426],"EGFR-panRASi":[91],"presented":[94],"for":[95,383,392,443],"concept":[96],"demonstration.":[97],"Methods:":[98],"GFS784":[99,123,137,166,217,230,265,272,284,324,334,350,360,387],"was":[100,124,138,167,221],"established":[101],"by":[102,140],"conjugating":[103],"Cetuximab":[104,317],"panRAS(ON)":[107,433],"GF005095":[109,196],"via":[110,169,291],"proprietary,":[112],"cleavable":[113],"linker":[114],"at":[115,285,320],"DAR":[116],"8.":[118],"anti-growth":[120,211],"tested":[125,278],"in":[126,171,186,215,226,237,270,279,282,298,331,340,363],"cell":[127,151,160,240],"lines":[128,241],"different":[130],"RAS":[131,248,394],"genotypes.":[132],"bystander":[134,268],"effect":[135,143,269],"investigated":[139],"comparing":[141],"growth":[146],"EGFR":[149],"negative":[150],"line":[152],"when":[153,277],"mono-cultured":[154],"or":[155,173,204,245,306,370,396],"co-cultured":[156],"EGFR-positive":[159],"line.":[161],"plasma":[163,275],"stability":[164,276],"studied":[168],"incubation":[170],"vitro":[172,280],"injection":[174],"into":[175,223],"mice.":[176,333],"CDX":[177,300,332,347,364],"tumor":[178,224,239,338],"mouse":[179],"models":[180,301,365],"were":[181,303],"used":[182],"explore":[184],"vivo":[187],"efficacy":[188,297,327],"GFS784.":[190],"Results:":[191],"pan-RAS(ON)":[193],"cyclophilin":[198],"A":[199],"target":[201],"K/H/N-RAS":[202],"mutants":[203],"wild":[205,246],"type":[206,247],"proteins":[207],"demonstrated":[209,266,325],"higher":[210],"than":[213,259],"DXd":[214,310,368],"vitro.":[216,271],"bound":[218],"internalized":[222],"cells":[225],"EGFR-dependent":[228],"manner.":[229],"showed":[231,273,294],"broad":[232],"potent":[234],"anti-proliferation":[235],"EGFR-expressed":[238],"addicted":[242],"mutant":[244,395],"genes":[249],"sub-nanomolar":[252],"median":[253],"IC50,":[254],"significantly":[257],"lower":[258],"that":[260],"EGFR-DXd":[263],"ADC.":[264],"significant":[267],"good":[274],"animals.":[283],"dose":[286],"levels":[287],"1-5":[289],"mg/kg":[290],"i.v.,":[292],"q3W":[293],"robust":[295],"RAS-mutant":[299],"either":[304],"sensitive":[305],"resistant":[307,344,366],"counterpart.":[311],"Compared":[312],"combination":[314],"therapy":[315],"using":[316],"RMC-6236":[319],"clinical":[321,402],"equivalent":[322],"doses,":[323],"comparable":[326],"but":[328],"better":[329],"tolerability":[330],"also":[335],"induced":[336],"deep":[337],"regression":[339],"both":[341],"Osimertinib-sensitive":[342],"EGFR-mutant":[345],"NSCLC":[346],"models.":[348],"Conclusions:":[349],"satisfactory":[353],"as":[356,375],"candidate.":[359],"Osimertinib,":[371],"suggesting":[372],"next-generation":[377,428],"alternative":[381],"solution":[382,391],"TKI":[384],"resistance.":[385],"Therefore,":[386],"provides":[388],"promising":[390],"treating":[393],"EGFR-altered":[397],"tumors":[398],"investigation":[403],"warranted.":[405],"Citation":[406],"Format:":[407],"Feng":[408],"Yan,":[409],"Jichen":[410],"Zhao,":[411],"Jingyang":[412],"Zhang,":[413],"Li":[414],"Wang,":[415],"Yumei":[416],"Li,":[417],"Siyuan":[418],"Le,":[419],"Fusheng":[420],"Zhou,":[421],"Jiong":[422],"Lan,":[423],"Qiang":[424],"Lu.":[425],"[abstract].":[436],"In:":[437],"Proceedings":[438],"American":[441],"Association":[442],"Cancer":[444,462],"Research":[445],"Annual":[446],"Meeting":[447],"2026;":[448],"Part":[449],"1":[450],"(Regular":[451],"Abstracts);":[452],"2026":[453],"Apr":[454],"17-22;":[455],"San":[456],"Diego,":[457],"CA.":[458],"Philadelphia":[459],"(PA):":[460],"AACR;":[461],"Res":[463],"2026;86(7":[464],"Suppl):Abstract":[465],"nr":[466],"4536.":[467]},"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-09-25T08:18:29.962427","created_date":"2026-04-04T00:00:00"}